Malignant neoplasm of lesser curvature of stomach, unspecified
ICD-10 C16.5 is a billable code used to indicate a diagnosis of malignant neoplasm of lesser curvature of stomach, unspecified.
C16.5 refers to a malignant neoplasm located at the lesser curvature of the stomach, which is a common site for gastric cancer. Gastric cancer is often associated with chronic infection by Helicobacter pylori (H. pylori), a bacterium that can lead to chronic gastritis and is a significant risk factor for the development of gastric adenocarcinoma. The staging of gastric cancer is crucial for determining treatment options and prognosis, typically classified using the TNM system (Tumor, Node, Metastasis). Treatment often involves surgical intervention, such as gastrectomy, which may be total or partial depending on the extent of the disease. Accurate coding for C16.5 requires careful documentation of the tumor's location, size, and any associated symptoms or complications, as well as the patient's history of H. pylori infection and treatment response.
Detailed pathology reports, imaging studies, and treatment plans.
Diagnosis and treatment planning for gastric cancer, staging assessments.
Ensure accurate documentation of tumor characteristics and treatment response.
Endoscopy reports, biopsy results, and H. pylori testing.
Management of gastric ulcers, chronic gastritis, and screening for gastric cancer.
Document any prior treatments for H. pylori and their outcomes.
Used for treatment of C16.5 in patients with localized disease.
Operative reports detailing the procedure and findings.
Ensure alignment with oncology and surgical documentation.
H. pylori is a major risk factor for gastric cancer, as it can cause chronic inflammation and increase the likelihood of malignant transformation in gastric tissue.
Gastric cancer is staged using the TNM system, which assesses the size and extent of the primary tumor, lymph node involvement, and the presence of metastasis.
Treatment options for C16.5 may include surgical resection (gastrectomy), chemotherapy, and targeted therapies, depending on the stage and overall health of the patient.
